This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Aquavit Pharmaceuticals Forms Alliance Partnership With Accelrys

NEW YORK, Sept. 21, 2012 /PRNewswire/ -- Aquavit Pharmaceuticals, Inc. and Accelrys Software Inc. (NASDAQ: ACCL), a leader in scientific innovation lifecycle management software, have formed an alliance partnership towards the development of Aquavit's PITO-001 and MAV-403 products.  The partner agreement was signed on September 12, 2012.  Under the terms of the partnership, Aquavit will utilize the scientifically aware Accelrys Enterprise Platform to develop advanced medical software for cutting-edge personalized medicine.

"It is an exciting opportunity for both companies.  As a leading global provider of enterprise scientific informatics software, Accelrys is the ideal partner to accelerate achievement of Aquavit's vision.  Having our products powered by the Accelrys Enterprise Platform will support our market leading science," said Sobin Chang, Aquavit's Chief Executive Officer.

"We are pleased to be partnering with Aquavit Pharmaceuticals to help accelerate the development of innovative personalized treatments," said Sanjay Gupta, Vice President of Corporate Development at Accelrys.  "The Accelrys Enterprise Platform will advance these initiatives by providing unparalleled capabilities in managing end-to-end scientific workflows to achieve better outcomes." 

This partnership will be led by Thomas S. Benjamin, Vice President of Technology at Aquavit Pharmaceuticals.  Mr. Benjamin's award winning research has appeared in The New York Times and The Wall Street Journal.  Mr. Benjamin said, "We aim to break new ground with the first-of-a-kind systems in our product lines.  We are thrilled to be integrating the powerful Accelrys Enterprise Platform into the development of our next-generation medical technologies."

About Aquavit Pharmaceuticals, Inc.Aquavit Pharmaceuticals is a multi-specialty healthcare company focused on discovering, developing and commercializing innovative pharmaceuticals, medical devices, and personalized health technologies.  Aquavit's business approach is enhanced by valuable global alliances.  Aquavit is developing an innovative drug delivery system that personalizes pharmaceutical solutions based on individual needs.  The company is based in New York City and Seoul.

About Accelrys Software, Inc.Accelrys (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves.  The industry-leading Accelrys Enterprise Platform provides a broad, flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development.  By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market.

Accelrys solutions are used by more than 1,300 customers in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries.  Headquartered in San Diego, Calif., Accelrys employs more than 200 full-time PhD scientists.  For more information about Accelrys, visit

SOURCE Aquavit Pharmaceuticals, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,761.96 -14.47 -0.09%
S&P 500 1,975.61 -11.44 -0.58%
NASDAQ 4,723.1430 -58.1210 -1.22%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs